COMPOSITIONS AND METHODS FOR INHIBITING THE SYNTHESIS OR EXPRESSION OF MMP-1 FOR TREATING, PREVENTING, OR MANAGING CANCER
Technologies Available for License Standard Agreements Invention Disclosure Invention Agreement Dartmouth Policies Trademark Program Annual Reports Related Sites		Overexpression of MMP-1 is associated with several pathological conditions, including the irreversible degradation of cartilage, tendon, and bone in arthritis and the degradation of collagens I and III in tumor invasion and metastasis. Patients with tumors that express MMP-1 have an overall poorer prognosis than patients with tumors that do not express this protein. Dartmouth researchers have now found that the expression of a MMP-1-specific short interfering RNA molecule in a breast cancer cell can significantly reduce the expression of MMP-1 mRNA and protein in the cancer cell, block the destruction of collagen matrix, and significantly decrease the size of tumors formed by these cells in nude mice. Accordingly, compositions which target MMP-1 nucleic acid sequences are expected to be useful in preventing, treating and managing cancer by suppressing invasion or metastasis of tumor cells. This technology is claimed in the published Patent Corporation Treaty Application No. PCT/US2005/020470. We are seeking an industrial partner interested in its commercialization. (Ref: J271)

		«Technology Transfer Office : Sponsored Projects : Dartmouth College
11 Rope Ferry Road #6210			E-Mail: technology.transfer@dartmouth.edu
Hanover, NH 03755-1404			Phone: (603) 646-3027
			Fax: (603) 646-3670